FDA Asks Drug Makers: How to Scale Without Breaking Rules
Published Date: 3/3/2026
Notice
Summary
The FDA wants to hear from drug makers and the public about how to improve their rules for making and changing certain medicines after approval. These rules help companies safely scale up production and tweak products without delays. Comments are open until June 1, 2026, so get your ideas in to help shape future guidance and keep medicine manufacturing smooth and cost-effective.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
SUPAC Reduces Approval Delays and Saves Industry
The SUPAC guidances are intended to reduce the number of chemistry, manufacturing, and controls (CMC) changes that require supplemental FDA approval. This can minimize delays in product distribution, give manufacturers more control over production resources, and result in significant net savings to industry.
FDA May Update SUPAC to Reflect New Science
The FDA is considering updating the SUPAC guidances to align with evolving science and other guidances (for example, ICH Q12) to improve their utility and effectiveness. These updates are intended to help manufacturers more effectively evaluate CMC changes within their quality systems before submitting them to FDA.
FDA Opens Public Docket on SUPAC
The FDA opened a public docket requesting information and comments on its SUPAC guidances and related documents. You can submit comments electronically or by mail and must do so by June 1, 2026, for the Agency to consider them before it begins work on any revisions.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2026-04195, Submission for OMB Review; Comment Request
The Department of Defense is asking for approval to collect info from 22,500 service members applying for or appealing Combat Related Special Compensation benefits. This new form helps decide who qualifies and lets denied applicants try again with new proof. Comments on this plan are open until April 2, 2026, and filling out the form takes about 15 minutes.
Next: 2026-04197, Certain Freight Rail Couplers and Parts Thereof from India: Preliminary Affirmative Countervailing Duty Determination and Alignment of Final Determination with Final Antidumping Duty Determination
The U.S. Department of Commerce found that Indian makers of certain freight rail couplers got unfair government help, so they’re planning to add extra taxes (countervailing duties) on these products. This affects Indian exporters and could make their couplers more expensive in the U.S. The final decision will line up with related antidumping duties, with key deadlines happening soon in 2026.